Treating Alzheimer’s with Cannabis Oils & Marijuana
In 2004, researchers found that cannabidiol (CBD) inhibits the release of the toxic beta-amyloidal peptide. This peptide is found in the Alzheimer’s brain.
THC reduces the agitation common in Alzheimer’s sufferers. Agitation is the most common behavior problem in patients with this disease (affecting 75%).
Alzheimer’s disease is another neurodegenerative condition for which cannabis (cannabinoid therapy) should work well in the treatment of its symptoms and the disease itself!
In 2004, researchers found that cannabidiol (CBD) inhibits the release of the toxic beta-amyloidal peptide. This peptide is found in the Alzheimer’s brain.
THC reduces the agitation common in Alzheimer’s sufferers. Agitation is the most common behavior problem in patients with this disease (affecting 75%).
Research done by the Scripps Research Institute in California shows that the active ingredient in marijuana, THC, prevents the formation of deposits in the brain associated with Alzheimer's disease. THC was found to prevent an enzyme called acetylcholinesterase from accelerating the formation of "Alzheimer plaques" in the brain more effectively than commercially marketed drugs. THC is also more effective at blocking clumps of protein that can inhibit memory and cognition in Alzheimer’s patients, as reported in Molecular Pharmaceutics.
Alzheimer's: New Method To Protect Brain Cells From Neurodegenerative Diseases Found
Researchers at LSU Health Sciences Center New Orleans, provides evidence that one of the only naturally occurring fatty acids in the brain that has the ability to interact with the receptors originally identified as the targets of THC (the psychoactive component of marijuana) can help to protect brain cells from neurodegenerative diseases like Alzheimer's and Parkinson's. Published in the Journal of Biological Chemistry, the research focuses on the cellular and molecular mechanisms of inflammation, specifically the role these relatively recently discovered endogenous cannabinoids can play in the control of COX-2 and other cyclooxygenases. COX-2 is a key player in neuroinflammation and has been implicated in the development of neurodegenerative diseases and worsening of damage from such insults as traumatic brain injury and stroke. The researchers show that endocannabinoid 2-arachidonoylglycerol (2-AG) functions as an endogenous COX-2 inhibitor, turning off the production of COX-2 which normally goes into overdrive in response to pro-inflammatory and certain types of toxic stimuli, resulting in the injury or death of brain cells. The researchers also revealed the specific signaling pathways that regulate the 2-AG suppression of COX-2. The findings provide a basis for opening up new therapeutic approaches to protect neurons from inflammation and toxicity-induced neurodegeneration, they said.